David has made over 3 trades of the Axovant Gene Therapies stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 22,157 units of AXGT stock worth $98,820 on 30 August 2018.
The largest trade he's ever made was selling 22,157 units of Axovant Gene Therapies stock on 30 August 2018 worth over $98,820. On average, David trades about 4,432 units every 6 days since 2016. As of 5 July 2018 he still owns at least 22,157 units of Axovant Gene Therapies stock.
You can see the complete history of Mr. Nassif stock trades at the bottom of the page.
David W. Nassif serves as Principal Financial and Accounting Officer and General Counsel, Chief Financial Officer of the Company. Mr. David served as Executive Vice President and Chief Financial Officer of SteadyMed, Ltd., a specialty pharmaceutical company, from March 2013 (first as a financial consultant and commencing March 2015 on a full-time basis) until June 2019. From May 2011 through September 2014, Mr. Nassif served as the President and Chief Financial Officer of Histogen, Inc., a regenerative medicine company. From May 2007 to February 2010, Mr. Nassif served as the Executive Vice President and Chief Financial Officer of Zogenix, Inc., a specialty pharmaceutical company. Mr. Nassif received a B.Sc. in Finance and Management Information Systems from the University of Virginia with honors and a J.D. from the University of Virginia School of Law.
As the Principal Financial and Accounting Officer and General Counsel a Chief Financial Officer of Axovant Gene Therapies, the total compensation of David Nassif at Axovant Gene Therapies is $1,761,210. There are 1 executives at Axovant Gene Therapies getting paid more, with Pavan Cheruvu having the highest compensation of $2,868,750.
David Nassif is 66, he's been the Principal Financial and Accounting Officer and General Counsel a Chief Financial Officer of Axovant Gene Therapies since 2019. There are no older and 7 younger executives at Axovant Gene Therapies.
David's mailing address filed with the SEC is C/O AXOVANT GENE THERAPIES LTD., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK, NY, 10036.
Over the last 5 years, insiders at Axovant Gene Therapies have traded over $0 worth of Axovant Gene Therapies stock and bought 5,401,703 units worth $20,204,515 . The most active insiders traders include Sciences Ltd. Roivant, Andrew Lo a Associates Gp Llcqvt Financ.... On average, Axovant Gene Therapies executives and independent directors trade stock every 65 days with the average trade being worth of $1,890,596. The most recent stock trade was executed by Atul Pande on 8 July 2020, trading 10,000 units of AXGT stock currently worth $27,300.
Axovant Gene Therapies Ltd., a clinical-stage company, develops gene therapies for neurodegenerative diseases. The company's product pipeline includes AXO-Lenti-PD program, an in vivo lentiviral gene therapy for the treatment of Parkinson's disease, which is in Phase II clinical trials; the AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis is in Phase I/II clinical trials; and the AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis that is in Phase I/II clinical trials. It has a license agreement with Oxford BioMedica (UK) Ltd.; license and collaboration agreement with Benitec Biopharma Limited; exclusive license agreement with The University of Massachusetts Medical School; and collaboration agreement with Invitae Corporation. The company was formerly known as Axovant Sciences Ltd. The company was founded in 2014 and is based in London, the United Kingdom.
Axovant Gene Therapies executives and other stock owners filed with the SEC include: